News & Events about Janux Therapeutics Inc.
Wedbush assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX Get Rating) in a report issued on Wednesday morning, The Fly reports. The firm issued an outperform rating and a $24.00 price objective on the stock. Other equities research analysts have also issued research reports about the ...
Wedbush initiated coverage on shares of Janux Therapeutics (NASDAQ:JANX Get Rating) in a research report report published on Wednesday, The Fly reports. The brokerage issued an outperform rating and a $24.00 target price on the stock. Several other research analysts have also commented on ...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today...
Market News Video
2years ago
In trading on Thursday, shares of Janux Therapeutics Inc (JANX) crossed above their 200 day moving average of 13.95, changing hands as high as 14.07 per share. Janux Therapeutics Inc shares are currently trading down about 0.1% on the day...